Tandem study shows benefits of its insulin pump tech in kids 

SAN DIEGO – Tandem Diabetes has published results from the pediatric artificial pancreas (PEDAP) clinical trial in the New England Journal of Medicine showing an increase of about three hours per day time in range in children ages 2-5 years old using the t:slim X2 insulin pump with Control-IQ advanced hybrid closed-loop technology compared to those on a standard insulin pump or multiple daily injections. “The safety and efficacy outcomes observed in this study support using Control-IQ technology for young children with type 1 diabetes to enhance quality of life and minimize the risk of long-term complications,” said Dr. R. Paul Wadwa, professor of pediatrics at the Barbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus and protocol chair for the PEDAP Clinical Trial. “Studies using Control-IQ technology have shown impressive results in different age groups, now in a sequence of randomized controlled trials published by the New England Journal of Medicine, demonstrating more time in range with low risk of hypoglycemia.” The study was a 13-week randomized, multi-center trial, featuring 101 children age 2 to <6 years old with Type 1 diabetes. It was funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) through a grant, with product support was provided by Tandem Diabetes Care and Dexcom, Inc. Previously, results from the Protocol 3 study (DCLP3) of the International Diabetes Closed Loop (iDCL) trial evaluating the use of Control-IQ technology in ages 14 and up, and from the Protocol 5 study (DCLP5) of the iDCL trial studying use in ages 6 to 13 were published by the New England Journal of Medicine in October 2019 and August 2020, respectively.